2024年12月25日 · P2RY6 (Pyrimidinergic Receptor P2Y6) is a Protein Coding gene. Diseases associated with P2RY6 include Frontotemporal Dementia And/Or Amyotrophic Lateral Sclerosis 7 and Parkinson's Disease. Among its related pathways are Purinergic signaling and GPCR downstream signalling.

High expression of P2RY6 was closely associated with a poor prognosis for patients, and it plays a role in regulating immune-related pathways, such as cytokine-cytokine receptor interaction. Notably, P2RY6 expression is closely linked to the abundance of CD8 + T cells.

2025年3月4日 · We found that inhibiting CYSLTR2/P2RY6 genetically or pharmacologically alleviated ceramide-induced atherosclerosis aggravation. Additionally, increased ceramide levels correlated with...

2024年10月22日 · The CPD accumulation and acute inflammatory response enhanced by the loss of the P2RY6 gene can be reversed by an AKT inhibitor. These findings suggest that P2RY6 may act as a tumor suppressor in UVB-induced skin …

P2RY6 is highly expressed in skin keratinocytes, but its function in skin diseases is unclear. We use a two-step chemical induction method to induce mouse skin tumor formation. Multiple in vitro and in vivo assays were used to explore the role of P2RY6 in skin tumors.

2025年2月8日 · Title: Tumor-intrinsic P2RY6 drives immunosuppression by enhancing PGE (2) production. Lipopolysaccharide-mediated ATP signaling regulates interleukin-6 mRNA expression via the P2-purinoceptor in human dental pulp cells.

Tumor-intrinsic P2RY6 drives immunosuppression by enhancing PGE2 production. Lipopolysaccharide-mediated ATP signaling regulates interleukin-6 mRNA expression via the P2-purinoceptor in human dental pulp cells.

2022年9月20日 · Purinergic receptors are powerful modulators of TLR-induced responses, and we here characterized the effects of P2Y6 receptor (P2RY6)-mediated signaling on TLR responses of rhesus macaque primary bone marrow-derived macrophages (BMDM) and microglia, using the selective P2RY6 antagonist MRS2578.

2024年7月23日 · Xu et al. identify P2RY6 as a key driver of immune evasion in cancers, promoting an immunosuppressive tumor microenvironment and resistance to immunotherapy, thus nominating P2RY6 as a precision immunotherapy target.

2024年6月6日 · We show that CDA in cancer cells contributes to the uridine diphosphate (UDP) pool. Extracellular UDP hijacks immunosuppressive tumor-associated macrophages (TAMs) through its receptor P2Y 6.